Revance Therapeutics Statistics
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
DCAC has 1.74 billion shares outstanding.
| Current Share Class | 1.74B |
| Shares Outstanding | 1.74B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +10.50% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| PB Ratio | -0.00 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.04
| Current Ratio | 0.04 |
| Quick Ratio | 0.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -4.64 |
| Interest Coverage | -0.77 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -36.91% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 16.11% |
| Revenue Per Employee | 2.17M |
| Profits Per Employee | -1.88M |
| Employee Count | 1 |
| Asset Turnover | 2.12 |
| Inventory Turnover | 7.79 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 1.52 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 46.30 |
| Average Volume (20 Days) | 1,128,199 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.00 |
Income Statement
In the last 12 months, DCAC had revenue of 2.17 million and -1.88 million in losses. Loss per share was -0.00.
| Revenue | 2.17M |
| Gross Profit | 816,995 |
| Operating Income | -604,128 |
| Pretax Income | -1.79M |
| Net Income | -1.88M |
| EBITDA | -448,990 |
| EBIT | -604,128 |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 49,071 in cash and 1.65 million in debt, giving a net cash position of -1.60 million or -0.00 per share.
| Cash & Cash Equivalents | 49,071 |
| Total Debt | 1.65M |
| Net Cash | -1.60M |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -4.00M |
| Book Value Per Share | -0.00 |
| Working Capital | -4.25M |
Cash Flow
In the last 12 months, operating cash flow was -468,522 and capital expenditures 112,967, giving a free cash flow of -355,555.
| Operating Cash Flow | -468,522 |
| Capital Expenditures | 112,967 |
| Free Cash Flow | -355,555 |
| FCF Per Share | -0.00 |
Margins
Gross margin is 37.67%, with operating and profit margins of -27.86% and -82.48%.
| Gross Margin | 37.67% |
| Operating Margin | -27.86% |
| Pretax Margin | -82.48% |
| Profit Margin | -82.48% |
| EBITDA Margin | -20.70% |
| EBIT Margin | -27.86% |
| FCF Margin | n/a |
Dividends & Yields
DCAC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -266.11% |
| Shareholder Yield | n/a |
| Earnings Yield | -107,927.97% |
| FCF Yield | -20,422.46% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 27, 2019. It was a reverse split with a ratio of 0.005.
| Last Split Date | Sep 27, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.005 |
Scores
DCAC has an Altman Z-Score of -36.85 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -36.85 |
| Piotroski F-Score | 3 |